The study is planned to enroll up to an additional 62 patients and the company plans to report interim data at upcoming medical conferences. More recently, we reported that two of the first three patients treated in the KEYNOTE-B84 study of pepinemab in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) experienced a complete response (CR). Data from a Phase 1b/2 clinical trial in non-small cell lung cancer shows that the combination of pepinemab with BAVENCIO® (avelumab), appears to increase the frequency of objective responses and extend progression-free survival relative to single agent avelumab. Pepinemab, in combination with a checkpoint inhibitor, has been found to significantly enhance T-cell infiltration and to simultaneously reduce immunosuppressive cells in tumors, a potentially powerful combination to increase anti-tumor activity. Food and Drug Administration or by any other health authority worldwide. There is no guarantee that pepinemab (VX15/2503) will be approved for the treatment of any disease by the U.S. It has not been demonstrated to be safe and effective for any disease indication. Note: Pepinemab (VX15/2503) is an investigational drug currently in clinical studies. Pepinemab’s mechanism of action is to block the SEMA4D signal so as to preserve normal functions and slow or prevent disease progression. In cancer, we discovered that tumors exploit expression of a high concentration of SEMA4D at their margins to block immune cell infiltration and suppress anti-tumor activity, contributing to mechanisms to evade immune protection against cancer.In chronic brain diseases, such as Huntington’s and Alzheimer’s disease, we have discovered that SEMA4D triggers neuroinflammation with an associated loss of normal brain functions that accelerates disease progression. SEMA4D is an extracellular signaling molecule that regulates the migration and activation of immune and inflammatory cells at sites of injury and cancer. VX15/2503 (USAN Council approved name "pepinemab") is a humanized monoclonal IgG4 antibody that binds and blocks the signaling activity of SEMA4D.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |